Predictive Biomarkers and Personalized Medicine Phase II Trial of MEK Inhibitor Selumetinib ( AZD 6244 , ARRY-142886 ) in Patients with BRAFV 600 E / K-Mutated Melanoma
暂无分享,去创建一个
M. Berger | J. Wolchok | N. Rosen | Sasinya N. Scott | D. Solit | M. Lacouture | G. Schwartz | P. Chapman | R. Carvajal | K. Panageas | M. Pulitzer | T. Iyriboz | Federica Catalanotti
[1] A. Lazar,et al. Clinical responses to selumetinib (AZD6244; ARRY‐142886)‐based combination therapy stratified by gene mutations in patients with metastatic melanoma , 2013, Cancer.
[2] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[3] C. Ng,et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma , 2012, Cancer.
[4] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[5] C. Berking,et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. , 2012 .
[6] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[7] B. Taylor,et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF , 2012, Oncogene.
[8] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[9] Nikhil Wagle,et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.
[10] R. Dummer,et al. Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma , 2011, Clinical Cancer Research.
[11] J. Infante,et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Xing,et al. Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 Mutations in Thyroid Cancers , 2011, Endocrine pathology.
[13] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[14] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[15] Prahlad T. Ram,et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. , 2010, Cancer research.
[16] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[17] B. Taylor,et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.
[18] W. Sellers,et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.
[19] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[20] R. Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[21] Chad A Mirkin,et al. Molecular printing. , 2009, Nature chemistry.
[22] M. Pincus,et al. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations , 2008, Oncogene.
[23] J. Stockman,et al. Distinct Sets of Genetic Alterations in Melanoma , 2007 .
[24] M. Pincus,et al. Novel mutations of epidermal growth factor receptor in localized prostate cancer. , 2006, Frontiers in bioscience : a journal and virtual library.
[25] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[26] Zhong Wen-zhao,et al. Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome , 2006 .
[27] R. Cusano,et al. Molecular characterization of Italian nevoid basal cell carcinoma syndrome patients , 2005, Human mutation.
[28] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.